An interdomain RNA binding site on the hepadnaviral polymerase that is essential for reverse transcription  by Badtke, Matthew P. et al.
Virology 390 (2009) 130–138
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roAn interdomain RNA binding site on the hepadnaviral polymerase that is essential for
reverse transcription
Matthew P. Badtke a,1, Irfan Khan a, Feng Cao a, Jianming Hu c, John E. Tavis a,b,⁎
a Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO, USA
b Saint Louis University Liver Center, Saint Louis University School of Medicine, 1100 S. Grand Blvd., St. Louis, MO, USA
c Department of Microbiology and Immunology, Pennsylvania State University College of Medicine, Hershey, PA, USA⁎ Corresponding author. Department of Molecular M
Saint Louis University School of Medicine, 1100 S. Grand
Tel.: +1 314 977 8893; fax: +1 314 977 8717.
E-mail address: tavisje@slu.edu (J.E. Tavis).
1 Current address: University of Michigan, Departm
Development Biology, 830 North University, Ann Arbor,
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.04.023a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 March 2009
Returned to author for revision 6 April 2009
Accepted 29 April 2009
Available online 24 May 2009
Keywords:
Hepatitis B virus
Hepadnavirus
Reverse transcription
Reverse transcriptase
RNA bindingThe T3 motif on the duck hepatitis B virus reverse transcriptase (P) is proposed to be a binding site essential
for viral replication, but its ligand and roles in DNA synthesis are unknown. Here, we found that T3 is needed
for P to bind the viral RNA, the ﬁrst step in DNA synthesis. A second motif, RT-1, was predicted to assist T3. T3
and RT-1 appear to form a composite RNA binding site because mutating T3 and RT-1 had similar effects on
RNA binding, exposure of antibody epitopes on P, and DNA synthesis. The T3 and RT-1 motifs bound RNA
non-speciﬁcally, yet they were essential for speciﬁc interactions between P and the viral RNA. This implies
that speciﬁcity for the viral RNA is provided by a post-binding step. The T3:RT-1 motifs are conserved with
the human hepatitis B virus and may be an attractive target for novel antiviral drug development.© 2009 Elsevier Inc. All rights reserved.IntroductionHepatitis B virus (HBV) is the prototypic member of the family
Hepadnaviridae, hepatotropic partially double-stranded (ds) DNA
viruses (Seeger et al., 2007). HBV chronically infects over 360 million
people and causes more than 600,000 deaths each year world-wide
(Shepard et al., 2006). It is a small DNA virus that replicates by reverse
transcription (Summers and Mason, 1982). The virion has a lipid
envelope studded with viral glycoproteins that surrounds an
icosahedral core particle. Within the core particle are the viral nucleic
acids and a virally-encoded reverse transcriptase, called the poly-
merase (P). Hepadnaviruses have been found in birds and mammals,
including ducks, herons, geese, ground squirrels, woodchucks, woolly
monkeys and humans (Schoedel et al., 1989; Guo et al., 2005; Lanford
et al., 1998). These viruses all have ∼3 kb partially dsDNA genomes
and replicate primarily in hepatocytes. Duck hepatitis B virus (DHBV)
is a common model for HBV.
Reverse transcription occurs in cytoplasmic subviral capsids and is
catalyzed by P. Reverse transcription is initiated by binding of P to the
viral pregenomic RNA template at a stem loop called ɛ (Pollack and
Ganem, 1994; Hirsch et al., 1990; Junker-Niepmann et al., 1990; Beckicrobiology and Immunology,
Blvd., St. Louis, MO 63104, USA.
ent of Molecular, Cellular and
MI 49109, USA.
ll rights reserved.and Nassal, 1997). Binding to ɛ induces a conformational change in P
that is necessary to trigger its enzymatic activity (Tavis and Ganem,
1996; Tavis et al., 1998). The P:RNA complex is then encapsidated
through polymerization of the viral core protein around it to form the
capsid. Reverse transcription is templated by a bulge in ɛ (Wang and
Seeger, 1993; Tavis et al., 1994) and is primed by a tyrosine residue on
P itself. The result of this unique protein-priming mechanism is that
the minus-strand DNA is covalently attached to P. Binding of P to ɛ and
reverse transcription are dynamic processes involving several con-
formational changes by P, at least some of which are mediated by
essential interactions with host chaperone proteins, including HSP90,
HSP70, HSP40, p23 and HOP (Beck and Nassal, 2003; Hu et al., 2002;
Hu and Seeger, 1996; Hu et al., 1997).
P has 4 domains (Fig.1A) (Chang et al., 1990; Radziwill et al., 1990).
The terminal protein domain contains the tyrosine that primes DNA
synthesis and covalently links P to the viral DNA (Y96 in DHBV, Y63 in
HBV) (Weber et al., 1994; Zoulim and Seeger, 1994; Lanford et al.,
1997). The spacer domain has no known function other than to link
the terminal protein domain to the rest of P. The reverse transcriptase
domain contains the DNA polymerase active site for reverse
transcription, and the RNAse H domain degrades the RNA template
during reverse transcription. The structure of P has not been solved
due to an inability to crystallize the protein. The HBV reverse
transcriptase and RNAse H domains have been modeled based on
structures of the Moloney murine leukemia virus (MMLV) and human
immunodeﬁciency virus (HIV) reverse transcriptases (Das et al., 2001;
Langley et al., 2007; Bartholomeusz et al., 2004; Potenza et al., 2007),
but there is no model for the terminal protein domain as it has no
Fig.1. Structural organization of P. (A) The four domains of DHBV P and their boundaries
are shown along with the location of T3, RT-1 and the mAb 6 and 11 epitopes. Black bars
represent P sequences employed as synthetic peptides. (B) miniRT2, an active
truncation of P, is shown with the boundaries of the truncations.
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with recombinant fragments of HBV P imply that there are multiple
contacts between the terminal protein domain and the reverse
transcriptase/RNAse H domains (Lanford et al., 1997; Lanford et al.,
1999), but the relative arrangement and contact points between the
domains are unknown. There are alsomany contacts between P and its
template ɛ, but the residues involved in these interactions are not
known.
We previously described a motif in the terminal protein domain
of DHBV P that is essential for DNA synthesis (Cao et al., 2005;
Badtke et al., 2006). We found that six monoclonal antibodies
(mAb) against the terminal protein domain were able to immuno-
precipitate enzymatically active P translated in vitro in a partiallyFig. 2. RNA binding by wild-type and T3-mutant P. (A) Co-precipitation RNA binding
radiolabeled ɛ or ɛ-dlBulge RNA, P was immunoprecipitated, and co-precipitating RNAs
mutations in T3. Wild-type and T3-mutant P molecules were assayed for the ability to bin
was immunoprecipitated and the speciﬁc activities of the RNAs. Error bars are the stan
(C) Mutating the T3 motif ablates encapsidation. LMH cells were transfected with CDN
expression vectors. Four days post-transfection intracellular DHBV core particles were har
blot. (D) The T3 peptide does not directly inhibit the DNA polymerase active site. 35S-lab
peptides were added at the indicated concentrations, an aliquot of the mixture was remov
priming assay was performed employing [α32P]dGTP. The samples were resolved by SDS-P
priming was detected as 32P-labeling of P (bottom panel). The 35S signal was blocked in th
included during translation. MBP, a peptide from myelin basic protein at 1.0 mM as a nedenaturing buffer (RIPA), but only three were able to immunopre-
cipitate P in a more physiological buffer (IPP150). Epitope mapping
revealed that the epitopes obscured in IPP150 ﬂanked a highly
conserved region (aa 176–183), which we named T3. Mutations to
T3 exposed the obscured mAb epitopes while simultaneously
inhibiting DNA priming by P, and mutant genomes with lesions in
T3 of both HBV and DHBV failed to synthesize DNA within cells.
Importantly, synthetic peptides containing T3 sequences speciﬁcally
inhibited priming in a dose-dependent manner. Based on these data,
we proposed that T3 is a molecular binding site on P needed for
enzymatic activity. This hypothesis was recently extended by Stahl
et al. (2007) who showed that the T3 motif we had identiﬁed was
exposed by the chaperones and that mutations within T3 could
disrupt RNA binding without causing a general disruption of protein
folding. These authors proposed that T3 may directly bind RNA
following its exposure by the chaperones. We now extend these
observations through RNA binding studies, mutagenesis and peptide
competition to identify T3 and a novel motif in the reverse
transcriptase domain called RT-1 as RNA binding sites essential for
reverse transcription.
Results
T3 is needed for P to bind to ɛ
The T3 motif (aa 176–183, EAGILYKR) is needed for P to prime
DNA synthesis (Cao et al., 2005), but T3 could contribute to ɛ
binding, enzymatic activation of P, and/or priming itself. Toassay. Wild-type P or P(I179D/L180D) were translated in vitro in the presence of
were resolved by electrophoresis. (B) RNA binding activity by derivatives of P with
d ɛ using the assay in panel A, and RNA binding was normalized to amount of P that
dard deviation from three experiments. ɛ RNA was employed except where noted.
A3.1 as a negative control or with wild-type or P(K182E/K183E) overlength DHBV
vested, the endogenous nucleic acids were removed, and P was detected by western
eled P was translated in the presence of ɛ (“During”) or absence of ɛ (“After”), the
ed to monitor translation efﬁciency, ɛ was added to the “After” reactions, and then a
AGE, translation efﬁciency was monitored by detecting 35S-labeled P (top panel), and
e priming reactions by overlaying the gel with exposed X-ray ﬁlm. Cx, cycloheximide
gative control.
Fig. 3. The T3 peptide can inhibit priming by miniRT2 in the absence of chaperones.
MiniRT2 was puriﬁed under denaturing conditions to remove the bacterial chaperones,
refolded, and incubated with ɛ and [α32P]dGTP in the presence or absence of the
indicated synthetic peptides. The left panel shows Coomassie blue stained miniRT2
following puriﬁcation. The right panel shows the priming signal following incubation of
miniRT2 with increasing concentrations of T3 or the irrelevant MBP peptide. Peptide
concentrations are in mM.
Fig. 4. T3 and RT-1 are conserved among the hepadnaviruses. Multiple sequence
alignments of regions ﬂanking T3 (A) and RT-1 (B). DHBV3 to RGHBV are avian hepad-
naviruses and WHV to HBV are mammalian hepadnaviruses.
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ﬁrst tested the ability of T3 mutants to bind ɛ. P was translated in
vitro, 32P-labeled RNA was added, and the mixture was incubated at
30 °C for 60 min. The complexes were immunoprecipitated using an
anti-P polyclonal antibody, and then P and the co-precipitated RNA
were resolved by electrophoresis (Fig. 2A). The RNAs employed
were ɛ, ɛ-dlBulge (a biologically inactive mutant form of ɛ that
binds P poorly) (Pollack and Ganem, 1994) and DRF+ (DHBV
nucleotides 2401–2605 as an irrelevant RNA). Following normal-
ization of the data to the amount of P precipitated and the speciﬁc
activities of the RNAs, P was found to bind ɛ seven-fold better than
ɛ-dlBulge and DRF+ (Fig. 2B). We also tested several T3 mutants,
some of which have been described previously (Cao et al., 2005), for
their ability to bind ɛ (Fig. 2A). P(Y170A/L171A) is a mutant with
lesions just upstream of T3 that primes DNA synthesis very poorly,
and it bound ɛ ∼50% as well as wild-type. P(Y181F), a mutant we
had shown previously to be wild-type in its priming ability (Cao et
al., 2005), bound ɛ better than wild-type P. However, two mutants
with lesions in T3 that were unable to prime DNA synthesis, P
(I179D/L180D) and P(K182E/K183E) (Cao et al., 2005), were
severely reduced in ɛ binding. Therefore, there was a correlation
between the ɛ binding and priming activities of P derivatives
carrying mutations in the T3 domain.
Binding of P to ɛ on the pregenomic RNA triggers hepadnaviral
encapsidation, and neither P nor the pregenomic RNA enters capsids
without formation of this ribonucleoprotein complex (Pollack and
Ganem, 1994; Bartenschlager et al., 1990). Therefore, mutating T3
should block encapsidation of P if T3 is needed for P to bind ɛ. To test
this prediction, overlength wild-type and T3-mutant P(K182E/K183E)
DHBV genomic expression vectors were transfected into LMH cells,
core particles were isolated, the particles were permeablized by low
pH treatment (Radziwill et al., 1988) and the covalently-attached
nucleic acids were degraded with micrococcal nuclease. P was then
resolved by SDS-PAGE and detected bywestern blot withmAb 11. Viral
core particles expressed from the wild-type genome contained P, but
cores expressed from genomes carrying the T3 mutation that ablated
RNA binding by P did not (Fig. 2C). Therefore, mutating T3 ablated
encapsidation in cells as was predicted by the failure of this mutant
enzyme to bind ɛ in vitro.
We previously demonstrated that a synthetic peptide containing
the T3 motif inhibits priming by P (Cao et al., 2005), and we
interpreted these data to indicate that the T3 peptide inhibits P by
competing for the ligand that binds to the T3motif. However, T3 could
have directly inhibited the DNA polymerase active site of P. To exclude
this possibility, we performed a priming assay with in vitro translated
P inwhich T3 or an irrelevant peptide was added either before or after
ɛ. The T3 peptide speciﬁcally inhibited P in a dose-dependent manner
when added before ɛ, as we had previously observed (Cao et al., 2005),but it inhibited P very poorly when added after ɛ (Fig. 2D bottom
panel). Because the T3 peptide was present at equal concentrations in
both cases yet it inhibited the enzyme only when added prior to ɛ, we
conclude that the T3 peptide did not directly target the DNA
polymerase active site.
Together, the correlation between the ɛ binding and priming
activities for the T3 mutants in vitro, the failure of P(K182E/K183E) to
encapsidated P in cells, and ability of the T3 peptide to inhibit priming
without directly inhibiting the DNA polymerase active site indicate
that the T3 motif functions to promote binding of P to ɛ.
T3 does not interact with cellular chaperones
We have hypothesized that T3 is a molecular binding site on P
(Cao et al., 2005), but binding at T3 could be intramolecular (with
another portion of P) or intermolecular (with a different molecule).
The most likely candidates for an intermolecular ligand would be
the ɛ-containing pregenomic RNA or the cellular chaperones that
bind to P.
To evaluate the possibility that the chaperones may bind to T3, we
employed miniRT2 (Fig. 1B), an active truncation of P that can prime
DNA synthesis in the absence of the chaperones (Wang et al., 2003). If
the T3 peptide inhibits priming by competing for binding of a
chaperone to the T3 motif on P, then it would not inhibit miniRT2 in
the absence of the chaperones. Therefore, we puriﬁed miniRT2 under
denaturing conditions to remove the bacterial chaperones that co-
purify with miniRT2 under native conditions (Wang et al., 2003) and
refolded the protein by gradually removing the denaturant. Incubation
of miniRT2 with the T3 peptide inhibited DNA priming, but three
irrelevant peptides had no effect (Fig. 3 and data not shown).
Therefore, an interaction between T3 and the molecular chaperones
cannot be needed for DNA priming by miniRT2. This conclusion was
conﬁrmed by co-immunoprecipitation studies employing full-length
P translated in vitro. Both wild-type P and P(I179D/L180D) (Fig. 2B),
which carries mutations in T3 that ablate RNA binding, could be co-
immunoprecipitated by antibodies against p23, a member of the
HSP90 chaperone complex (data not shown). Together, these data
indicate that the ligand for T3must be another region of P itself and/or
ɛ, as these were the only macromolecules present in the miniRT2
priming reaction.
Fig. 5. RT-1 is predicted to be on the surface of the reverse transcriptase domain. HBV RT-1 sequences were mapped onto the predicted structure of the HBV reverse transcriptase
domain (Das et al., 2001). Yellow, RT-1; green, thumb; red, palm; blue, ﬁngers; white, nucleic acids.
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We ﬁrst evaluated the possibility that T3may interact with another
region of P by examining the sequence of P for motifs that could be
potential ligands for T3. The spacer and RNAse H domains were
excluded because these regions are not present in miniRT2. Motifs in
the terminal protein domain that we had previously screened for their
ability to inhibit priming as synthetic peptides (unpublished data)
were considered unlikely to be the ligand for T3. The universally-
conserved motifs in the reverse transcriptase domain (Poch et al.,
1989; Delarue et al., 1990; Xiong and Eickbush, 1990) were also
considered to be unlikely to be a ligand for T3 because their molecular
functions are well characterized. Finally, we hypothesized that the
ligand would be conserved among the avian and mammalian
hepadnaviruses because T3 is highly conserved (Fig. 4A). The region
that ﬁtted these four criteria best was aa 385–415 near the N-terminus
of the reverse transcriptase domain (Fig. 4B), which we named RT-1.
If RT-1 binds to another region of P it would have to be on the
surface of the reverse transcriptase domain. While no crystalFig. 6. Effects of mutations to T3 and RT-1 on RNA binding, priming, and exposure of the m
exposure of the occluded mAb 6 epitope are shown for mutations to T3 and RT-1. All activit
of effects on the three activities are indicated with black dots. The error bars represe
(C) Representative mAb6 exposure data. (D) Representative RNA binding data. Note that pastructures exist for P, a reliable model has been developed for the
reverse transcriptase domain of HBV P (Das et al., 2001). Most of the
HBV RT-1 sequences were on the surface of the reverse transcriptase
domain model at one end of the DNA binding cleft (Fig. 5). This would
allow these sequences to interact with the terminal protein, which
contains the Y96 residue that must enter the active site during protein
priming. Alternatively, this motif would be equally well-positioned to
interact with the viral nucleic acids during reverse transcription.
Mutations within RT-1 simultaneously inhibit priming, expose an
epitope near T3 and reduce binding to ɛ
Mutating T3 inhibits priming, exposes buried mAb epitopes near
T3 in the terminal protein domain and inhibits binding to ɛ (Cao et al.,
2005). If RT-1 functions in concert with T3, either directly through
intramolecular binding or indirectly through binding of both motifs to
ɛ, then the effects of mutating RT-1 should be similar to the effects of
mutating T3. To test this prediction, we created ten sets of mutations
within RT-1. The majority of these substitutions were non-Ab6 epitope. (A) The relative effects on binding to ɛ, priming DNA synthesis, and the
ies are normalized to the activity of wild-type P. Mutations with the predicted pattern
nt±1 standard deviation from 3–4 experiments. (B) Representative priming data.
nels B–C are composites from multiple independent experiments.
Table 1
Effects of T3 and RT-1 peptides on priming.
Peptide DHBV residues Priming IC50a
T3-Scramble 174–185 975±283
T3 174–185 302±67
T3A 169–186 47±20
T3B 169–192 11±2
T3C 169–198 10±1
RT1A 383–399 630±65
RT1B 400–417 511±131
RT1C 381–416 46±12
a Values in μM,±1 standard deviation from three to ﬁve experiments.
Fig. 7. T3 and RT-1 peptides bind RNA. (A) T3 and RT-1 peptides bind ɛ. Top: The
peptides were bound to a nitrocellulose ﬁlter in a slot-blot apparatus and then 32P-
labeled ɛ RNAwas passed through the ﬁlter and the ﬁlter was washed. T3-Scramble and
T3B-Scramble are negative control peptides in which the sequences have been
scrambled; UL13 and Pep1 are irrelevant peptides. Bottom: T3B and RT1C peptides
were loaded onto a ﬁlter in amounts ranging from 10 pMol to 0.3 pMol and RNA binding
to 32P-labeled ɛ RNA was measured as in the top panel. (B) T3 and RT-1 peptides bind
nucleic acids non-speciﬁcally. Top: Filter binding assays were performed with T3 and
RT-1 peptides and either ɛ or the biologically inactive ɛ-dlBulge RNA in the presence or
absence of a 50-fold excess of non-radioactive yeast tRNA. Bovine serum albumen (BSA)
was used as an irrelevant protein. Bottom: Filter binding assays were performedwith T3
and RT-1 peptides and 32P-labeled DHBV core gene RNA or double-stranded DNA as
irrelevant nucleic acid probes.
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T3:RT-1 interface that would exist if these motifs bound to each other.
P derivatives with mutations to either T3 or RT-1 were translated in
vitro and their ability to prime DNA synthesis, to expose the occluded
mAb 6 epitope and to bind ɛwas tested (Fig. 6). As we had previously
observed, all mutations to the T3motif except Y181F had the predicted
pattern of activities. All ten mutants with lesions in RT-1 were less
active than wild-type P in the priming assay and seven retained≤5%
activity, indicating that RT-1 is important for DNA priming. Exposure
of the mAb 6 epitope was increased in eight of the 10 mutants,
whereas seven mutations to P outside of T3 or RT-1 had no effect on
exposure of the occluded mAb epitopes (P2A, K153E, P195V, D513H/
D514A, T668V/T670V, H693Y, and D715V; data not shown). Finally,
seven of the mutants bound ɛ less efﬁciently thanwild-type P. Overall,
seven of the ten RT-1 mutants had the expected pattern of reduced
priming, increased epitope exposure and reduced ɛ binding (indicated
by dots in Fig. 6), although the magnitudes of effects were usually
smaller than when T3 was mutated.
Six of the seven RT-1 mutants with the predicted pattern of
phenotypic effects had lesions near the N- or C-terminal ends of RT-1
(amino acids 383–392 and 404–429), and only one was near the
center of RT-1 (N399A/E402A), whereas the three mutants that did
not have the predicted pattern had substitutions near the middle of
RT-1 (residues 394–404). This central region of RT-1 is predicted to be
buried within the reverse transcriptase domain (Fig. 5), and partial
proteolysis indicates that residues 401 and 402 are not accessible to
digestion in DHBV P (Lin et al., 2008). Therefore, the complex effects of
mutating the central domain appear to have been due to disrupting
the fold of the reverse transcriptase domain by altering buried
residues. Overall, these data are consistent with sequences of both T3
and RT-1 contributing to RNA binding, either through interactionwith
each other or with RNA. However, these data do not exclude other
possible roles for RT-1 in DNA synthesis.
Synthetic peptides containing T3 and RT-1 sequences inhibit priming
A peptide containing T3 sequences speciﬁcally inhibits DNA
priming in a dose-dependant manner [Fig. 3 and Cao et al. (2005)].
If RT-1 binds to either T3 or ɛ, peptides containing RT-1 sequences
should also speciﬁcally block priming. Therefore, we created 3
peptides containing RT-1 sequences (Table 1). RT1A contains the N-
terminal half of RT-1 (aa 383–399), RT1B contains the C-terminal half
(aa 400–417) and RT1C contains the entire RT-1 sequence (aa 381–
416). We also created three larger T3 peptides in an attempt to
improve activity of the T3 peptide because the original T3 peptide was
active only at high concentrations. Finally, we created T3-Scramble
and T3B-Scramble, negative control T3 and T3B peptides in which the
residues were scrambled. To determine the effects of these peptides
on priming, increasing amounts of the peptides were added to P
following termination of in vitro translation with cycloheximide, and
the IC50 value for each peptide was calculated. The scrambled T3
peptide was essentially unable to inhibit priming (IC50−975 μM) and
the original T3 peptide had a high IC50 (302 μM) (Table 1). The new T3peptides all had IC50 values below 50 μM, with T3B and T3C having
values near 10 μM. The RT1A and RT1B peptides were poor inhibitors
of priming, with IC50 values greater than 500 μM. However, RT1C was
an effective inhibitor, with an IC50 of 46 μM. The RT-1 sequences
needed to be present on a single molecule because mixing RT1A and
RT1B did not inhibit priming any better than RT1A and RT1B
individually (data not shown). Therefore, both T3 and RT-1 peptides
efﬁciently inhibited priming, as predicted.
T3 and RT-1 peptides bind RNA
The preceding data indicate that T3 and RT-1 function in a similar
manner, but they are equally consistent with intramolecular binding
between the two motifs producing a conformation in P competent for
RNA binding, or with T3 and RT-1 forming a joint RNA binding site. To
help resolve these twomechanisms, we asked whether the T3 and RT-
1 peptides could bind RNA. The peptides (10 pMol) were bound to a
nitrocellulose ﬁlter in a slot-blot apparatus and the ﬁlter was washed.
Radiolabeled ɛ or its biologically inactive derivative ɛ-dlBulge were
added with or without a 50-fold excess of yeast tRNA, the ﬁlter was
washed, and retained RNA was detected by autoradiography (Fig. 7A
Fig. 8. Priming and RNA binding activities of miniRT2 and miniRT2 derivatives with lesions in T3 and RT-1. (A) MiniRT2, miniRT2–T3m, and miniRT2–RT1m puriﬁed under native
conditions. Note that the bacterial chaperones co-purify withminiRT2 under native conditions but they are removedwhen the puriﬁcation is performed under denaturing conditions
(compare Panel A and Fig. 3). B. Mutating the T3 and RT-1 motifs of miniRT2 ablates DNA priming. Equal amounts of DHBV miniRT2 and its T3m and RT1m derivatives were assayed
for their ability to prime DNA synthesis using either ɛ or its inactive derivative ɛ-dlBulge as templates. (C) RNA binding by miniRT2 is non-speciﬁc. RNA binding by equal amounts of
miniRT2 and its T3m and RT1m derivatives was tested in a ﬁlter-binding assay employing 32P-labeled ɛ and ɛ-dlBulge RNAs as probes in the presence or absence of a 50-fold excess of
unlabeled tRNA competitor.
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(UL13 and Pep1), nor to T3-Scramble or T3B-Scramble. However,
robust binding to the T3, T3B, T3C, and RT1C peptides was detected.
RNA binding was proportional to the amount of RNA loaded onto the
ﬁlter, and the RT1C peptide bound RNA less well than the T3B peptide
(Fig. 7A bottom panel). RNA binding was non-speciﬁc because the
peptides bound well to both ɛ and ɛ-dlBulge and because binding was
suppressed by an excess of unlabeled tRNA (Fig. 7B top panel). The
T3B and RT1C peptides were also able to bind to an irrelevant RNA
derived from the DHBV core gene and to a double-stranded DNA
fragment (Fig. 7B bottompanel). Therefore, peptides containing either
T3 or RT-1 sequences possess non-speciﬁc nucleic acid binding
activities. This strongly implies that these motifs bind to RNA in the
context of the intact protein.
Priming and RNA binding activities of miniRT2
We extended these binding studies from peptides to miniRT2
because miniRT2 retains ɛ-speciﬁc priming activity, is able to bind ɛ
without the aid of the cellular chaperones, and can be puriﬁed easily
from bacteria. Therefore, miniRT2 performs the authentic DNA
priming reaction but it is more experimentally tractable than full-
length P.
Wild-type miniRT2 and miniRT2 carrying the K182E/R183E
mutations in T3 (T3m) or the S410A/S413A mutations in RT-1
(RT1m) that impair RNA binding by the full-length P (Fig. 6) were
expressed in Escherichia coli and puriﬁed under native conditions by
nickel-afﬁnity chromatography. As expected, the miniRT2 proteins co-
puriﬁed with bacterial chaperones (Fig. 8A). MiniRT2 and equal
amounts of the twomutant proteins were incubated with ɛ and [α32P]
dGTP, the reactions were resolved by SDS-PAGE, and priming activity
was detected as 32P labeling of miniRT2 due to the covalent linkage of
[32P]dGMP to the enzyme (Fig. 8B). Themutations to T3 and RT-1 both
ablated priming by miniRT2, as they did in the context of full-length
P (Fig. 6).
We next assessed RNA binding by miniRT2 and its T3m and RT1m
mutants employing the ﬁlter-binding assay we used previously for the
peptides.Wild-typeminiRT2 bound both ɛ and its biologically inactive
derivative ɛ-dlBulge, and this binding was efﬁciently competed by a
50-fold excess of unlabeled yeast tRNA (Fig. 8C). Therefore, miniRT2
bound RNA non-speciﬁcally under these conditions just as the T3 and
RT-1 peptides did, although it can also bind ɛ speciﬁcally when
conditions favoring speciﬁc binding are employed (Hu et al., 2004).
MiniRT2–T3m failed to bind RNA under identical conditions. This was
expected because thesemutations ablate RNA binding by full-length P.However, the RT1mmutations increased RNA binding by about 2-fold
compared to the same amount of wild-type miniRT2. This result was
unexpected because the RT1m mutations reduce RNA binding by full-
length P to ∼5% of wild-type levels. RNA binding by miniRT2 and its
T3m and RT1m derivatives was not distorted by the solid-phase assay
we employed because identical results were obtained using GST-
taggedminiRT2 and its T3 and RT1 derivatives in a GST pull-down RNA
co-precipitation assay (data not shown). Therefore, the increased RNA
binding by the RT1m mutant has three implications. First, S410 and
S413 are not essential for RNA binding. Second, although the
mutations to RT-1 did not have the predicted effect, they didmodulate
RNA binding, and this strengthens our hypothesis that RT-1 is involved
in RNA binding by P. Finally, priming activity can be dissociated from ɛ
binding by mutating an RNA binding site on miniRT2.
Discussion
We previously identiﬁed the T3 motif in the terminal protein
domain of DHBV P as being essential for DNA synthesis in vitro and in
cells, and we demonstrated that ablating the HBV T3 motif eliminates
DNA synthesis in cells (Cao et al., 2005). We proposed that the T3
motif was a binding site on P and that “proper occupancy” of T3 was
essential for DNA synthesis because the effects of mutating T3 could
be mimicked by detergent treatment and competition with a soluble
peptide. These results were extended by Stahl et al. (2007) who
showed that T3 is transiently exposed on the surface of P by cellular
chaperones and that mutations within T3 that ablated RNA binding
did not cause large changes in the structure of P. They concluded that
T3 most likely directly bound ɛ, and they presented a model in which
cellular chaperones shuttle P between open and closed conformations,
with the open conformation exposing T3 so it could bind RNA. Here,
we further extend these studies with three novel observations. First,
we describe RT-1 as a region of the reverse transcriptase domain that
is functionally linked with T3 and that together with T3 promotes
binding to ɛ. Second, we show that T3 and RT-1 peptides directly bind
RNA. Finally, we present data implying that the initial RNA binding by
P is non-speciﬁc.
These data lead us to hypothesize that the T3 and RT-1 motifs form
a composite RNA binding site to which ɛ binds during the ﬁrst step of
reverse transcription. We favor this hypothesis for ﬁve reasons. First,
T3 and RT-1 peptides directly bind RNA (Fig. 7). Second, mutations to
T3 or RT-1 inhibit binding of full-length P to ɛ (Fig. 6). The
participation of T3 and RT-1 in RNA binding is supported by alanine-
scanning mutagenesis across DHBV P (Seeger et al., 1996); one
mutation to T3 and six to RT-1 were analyzed, and the results were
136 M.P. Badtke et al. / Virology 390 (2009) 130–138fully consistent with our observations. Third, both T3 and RT-1 appear
to be at least transiently exposed on the surface of P. Stahl et al. have
demonstrated that T3 is transiently exposed during RNA binding
(Stahl et al., 2007), Lin et al. (2008) have shown that residues ﬂanking
T3 are accessible to partial proteolysis, and molecular modeling
implies that RT-1 is largely solvent-exposed (Das et al., 2001) (Fig. 5).
Fourth, three of the four sets of mutations we created in T3 and seven
of the 10 sets in RT-1 simultaneously reduced RNA binding, increased
exposure of the occluded mAb 6 epitope, and inhibited priming (Fig.
6). Finally, mapping studies employing truncated derivatives of HBV
and DHBV P revealed that sequences from both the terminal protein
domain (including T3) and from the reverse transcriptase domain
(including RT-1) are needed for P to bind RNA (Wang et al., 1994; Hu
and Boyer, 2006; Pollack and Ganem, 1994; Hu and Anselmo, 2000).
The simplest interpretation of these data is that the T3 and RT-1motifs
cooperate to form the initial RNA binding site on P.
T3 and RT-1 may have structural roles in addition to their RNA
binding activities because mutating T3 and RT-1 exposes antibody
epitopes in the terminal protein domain that are normally obscured
[Cao et al. (2005) and Fig. 6]. The simplest scenario would be that
the RNA blocks access of the antibodies to their epitopes. However,
the epitopes on in vitro translated P remain obscured in the absence
of ɛ (data not shown), so either the non-speciﬁc RNAs in the
translation mixture compete with the antibodies for binding to P, or
T3 and RT-1 help maintain a conformation of P in which the
epitopes are obscured. We favor a conformational role for these
motifs because the afﬁnity of the non-speciﬁc RNA for P is unlikely
to be high enough to compete with binding of the monoclonal
antibodies. A plausible mechanism would be for T3 and RT-1 to bind
to each other in the closed conformation, but experimental evidence
for this possibility is lacking.
Our data and those of Stahl et al. (2007) can be combined into a
model for the early stages of reverse transcription (Fig. 9). In this
model, newly translated P binds to the cellular chaperones and forms
the Closed Complex. This complex contains P in an inactive conforma-
tion (Tavis and Ganem, 1996; Tavis et al., 1998), where T3 (Stahl et al.,
2007) and perhaps RT-1 are occluded. Cellular chaperones convert the
closed complex into the Open Complex, where T3 (and presumably RT-
1) is transiently exposed (Stahl et al., 2007). If the open complex
encounters a non-ɛ RNA, it forms a Non-productive Complex in which
the RNA binds weakly to T3 and RT-1. Dissociation of the RNA causes P
to revert to the open complex, which in turn could revert to the closed
complex, where the chaperones may restart the cycle. Reversibility of
these steps is supported by the shuttling of P between the closed and
open complexes (Stahl et al., 2007), and because the vast excess of
non-ɛ RNAs over ɛ within cells would effectively prevent P from
ﬁnding ɛ if these reactions were not reversible.Fig. 9. Model for the contribution of T3 and RT-1 to the initial events of reverse transcripti
relationship to the position of the DNA polymerase active site (AS). The domains of P are shIf the open complex binds to ɛ, it would create the Productive
Complex, where T3 and RT-1 bind ɛ. The productive complex may be a
transient intermediate in which ɛ contacts P in much the same
manner as other RNAs, or ɛ could be held in contact with P through
novel protein-RNA contacts. The existence of the productive complex
as a discrete state is supported by ɛ derivatives with mutations in the
apical loop which bind to P but cannot support priming (Pollack and
Ganem, 1994; Tavis and Ganem, 1996; Hu and Boyer, 2006). Following
formation of the productive complex, speciﬁc interactions between ɛ
and P would cause an induced-ﬁt conformational change in P
detectable as partial resistance of P to proteolysis (Tavis and Ganem,
1996; Tavis et al., 1998). This creates the Priming Complex, the form of
the enzyme which can prime DNA synthesis. The P:ɛ interactions
needed for conversion to the priming complex are poorly character-
ized, but as discussed above, they probably include speciﬁc interac-
tionswith the apical loop of ɛ. Alternatively, a cellular protein has been
hypothesized to bind to the apical loop of ɛ (Pollack and Ganem,1994;
Hu and Boyer, 2006), and in this case contacts between the
hypothetical protein and P would promote progression to the priming
complex.
We propose that the transition from the productive to priming
complexes is not readily reversible and that this irreversibility is the
primary source of the speciﬁcity of P for ɛ. Conﬂicting data have been
reported on this issue. Wang et al. (1994) demonstrated that P can
prime DNA synthesis if ɛ is restored following its removal from in vitro
translated P with RNAse A, but they could not demonstrate that the
molecules that primed DNA synthesis had bound ɛ in the ﬁrst phase of
the experiment. We used partial proteolysis to show that P cannot re-
engage ɛ and return to the priming complex following removal of ɛ
(Tavis and Ganem, 1996), but priming activity was not directly
measured. Regardless of the mechanism, P loses its ability to engage
exogenous nucleic acids shortly before or after it primes DNA
synthesis, a property that has been dubbed “template commitment”
(Radziwill et al., 1988).
Key features of this model are: 1) RNA binding by P involves direct
interactions between the T3 and RT-1 motifs and the RNA; 2) initial
RNA binding by P at the T3/RT-1 site is non-speciﬁc; and 3) the
preference of P for ɛ over non-ɛ RNAs (Fig. 2B) is primarily due to
induced-ﬁt conformational changes to both P and ɛwhich trap ɛ in the
priming complex. The initial non-speciﬁc RNA binding step is themost
novel part of this model. Its existence is supported by the ability of the
T3 and RT-1 peptides and miniRT2 to bind ɛ and non-ɛ RNAs equally
well. Non-speciﬁc RNA binding by P has not been explicitly reported
because prior RNA binding studies by us and others have been done in
the presence of excess irrelevant RNAs, and consequently were
designed to detect speciﬁc binding to ɛ. However, full-length P clearly
possesses both non-speciﬁc and ɛ-speciﬁc RNA binding activitieson. See text for details. The putative locations of the T3 and RT-1 motifs are shown in
aded as in Fig. 1.
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∼7-fold.
The model in Fig. 9 implies that the bulge within ɛ that templates
priming must be passed from the T3/RT-1 site to the DNA polymerase
active site after ɛ has bound to P. This could occur either by
translocation of ɛ into the active site or through unfolding of ɛ to
allow the bulge to reach the active site. The unfolding mechanism is
plausible because unfolding of the upper stem of ɛ upon binding to P
has been reported (Beck and Nassal, 1998). A role for RT-1 sequences
in the transfer to the active site is supported by the S410A/S413A
mutation (“RT1m” in Fig. 8). MiniRT2 containing the S410A/S413A
lesion bound RNA better than wild-type miniRT2, yet it was unable to
prime DNA synthesis (Fig. 8), genetically resolving these events in the
context of miniRT2. However, interpreting the role of S410A/S413A in
RNA binding and priming is complicated because this lesion reduced
RNA binding by full-length P 20-fold (Fig. 6). This discrepancy may be
due to our experimental design: RNA binding by full-length P was
measured under conditions favoring speciﬁc ɛ binding, and conse-
quently reﬂects RNA binding by P in the priming complex (Fig. 9). In
contrast, RNA binding by miniRT2 was measured under non-speciﬁc
conditions that primarily reﬂect RNA binding by enzyme in the
productive complex.
Most therapies for HBV employ one of ﬁve nucleoside/nucleotide
inhibitors that target the DNA polymerase active site on P. Drug
resistant mutations frequently arise during therapy, including some
that are cross-resistant between drugs (Bartholomeusz and Locarnini,
2006; Ghany and Liang, 2007). Therefore, there is a great need for
drugs with novel targets. The T3:RT-1 interactionwith RNA is essential
for reverse transcription and can be disrupted with soluble compe-
titors, and hence the T3:RT-1 RNA binding site should be a viable drug
target. Porphyrin compounds can inhibit binding between P and ɛ, and
these compounds appear to target sequences in both the terminal
protein and reverse transcriptase domains, consistent with possible
inhibition of the T3:RT-1 site (Lin andHu, 2008). The T3:RT-1 interface
is particularly attractive because resistance mutations to drugs
targeting T3:RT-1 would be very unlikely to be cross-resistant to
drugs that target the DNA polymerase active site. Therefore, anti-T3:
RT-1 drugs would be excellent complements to the nucleoside/
nucleotide inhibitors, permitting true combinational therapy against
HBV for the ﬁrst time.
Materials and methods
Viruses and DNA clones
pT7BDPol contains DHBV strain 3 (Sprengel et al., 1985) nucleo-
tides (nt) 170 to 3021 encoding P within pBluescript (Stratagene); the
construct contains a 33-nt insertion at DHBV nt 901 encoding the
inﬂuenza virus hemagglutinin epitope (Kolodziej and Young, 1991) as
well as leader sequences from Brome mosaic virus to promote
translation in vitro. Mutations (Table 1) were inserted into pT7BDPol.
The plasmid pdɛ contains DHBV nt 2526 to 2845 encoding ɛ within
pBluescript. pdɛ-dlBulge is pdɛ with a deletion of nt 2571–2576.
pDCore contains DHBV nt 2649–414 in the vector pRSETc (Invitrogen).
pDRF-BS contains DHBV nt 2401–2605 in pBluescript.
Bioinformatics
Amino acid sequences were aligned using Clustal W. Accession
numbers for the sequences employed are DQ195079 (Duck hepatitis
B virus, DHBV), CAC80820 (Stork hepatitis virus, SHV), AAA45738
(Heron hepatitis virus, HHV), AAA45748 (Ross' goose hepatitis virus,
RGHV), AAA46767 (Woodchuck hepatitis virus, WHV), P03161
(Ground squirrel hepatitis virus, GSHV), AAC16908 (Woolly monkey
hepatitis virus, WMHV) and AM282986 (Hepatitis B virus, HBV).
The coordinates for the model of the HBV reverse transcriptasedomain (Das et al., 2001) were displayed using Pymol (DeLano
Scientiﬁc).
In vitro transcription and translation
mRNAs for DHBV P and Core were transcribed with T7 RNA
polymerase from pT7BDPol and pDCore respectively. ɛ and ɛ−dlBulge
RNAs were transcribed with T3 RNA polymerase from pdɛ and pdɛ-
dlBulge. All RNAs were transcribed using Megascript kits (Ambion)
according to the manufacturer's instructions. In some cases 32P-
labeled RNAs were transcribed by including 25 μCi of [α32P]UTP
(3000 Ci/mmol, GE Healthcare) in the reaction. 35S-labeled DHBV P
was translated in vitro employing rabbit reticulocyte lysates (Pro-
mega) in 10 or 20 μl total volume containing [35S]methionine
(1000 Ci/mmol; GE Healthcare) at 30 °C for 1.5 h according to the
manufacturer's instructions.
MiniRT2 puriﬁcation and refolding
MiniRT2 containing a hexa-histidine tag on the N-terminus was
expressed and puriﬁed by nickel-afﬁnity chromatography under
both denaturing and native conditions. Puriﬁcation under denatur-
ing conditions was as previously described (Wang et al., 2003),
with minor changes. Brieﬂy, the bacterial pellet was suspended in
6 M guanidine–HCl along with 20 mM imidazole and 0.1% NP40.
After cell lysis the protein was bound to Ni-NTA agarose beads
(Qiagen) and washed with 8 M urea. While still attached to the
beads, the protein was refolded by adding refolding buffer (Wang et
al., 2003) along with decreasing amounts of urea. Elution buffer
[50 mM hepes (pH 8.0, 350 mM imidazole, 300 mM NaCl, 0.1%
NP40 and 27.5% glycerol] was used to release the protein from the
beads, followed by dialyzing overnight in 50 mM hepes (pH 8),
0.1 M NaCl, 20% glycerol, 0.2% NP40, 50 mM dithiothreitol and
protease inhibitor cocktail (Sigma). Native puriﬁcation of miniRT2
and its T3m and RT1m derivatives employed conditions established
for hexa-histidine tagged Hepatitis C virus NS5B RNA polymerase
(Ferrari et al., 1999).
Priming assay
35S-labeled P was translated in vitro and an aliquot was removed to
measure translation efﬁciency. 10 μCi [α32P]dGTP (3000 Ci/mmol, GE
Healthcare), 0.25 μg ɛ andMgCl2 to 4mMwere added and themixture
was incubated at 30 °C for 30 min. The samples were then resolved by
SDS-PAGE and the translation and priming signals were quantiﬁed
using a phosphorimager. The priming signal was normalized to
translation efﬁciency. DNA priming by miniRT2 was assessed using
200 ng puriﬁed miniRT2 in TMNK buffer (20 mM Tris pH 7.5, 2 mM
MgCl2, 15 mM NaCl, 20 mM KCl, and 4 mM dithiothreitol) plus 0.5%
NP40 as described previously (Wang et al., 2003). Synthetic peptides
(Genscript) were included in some experiments. The sequence of the
MBP peptide in Fig. 2 is APRTPGGRR.
RNA binding assays
The P:RNA binding assay described previously (Beck and Nassal,
1997) was used with minor modiﬁcations. Wild-type or mutant P
was translated in vitro in the presence of 250 ng of 32P-labeled RNA.
Translation was stopped by addition of cycloheximide (80 μM), and
then the P:RNA complex was immunoprecipitated using the anti-
DHBV P polyclonal antibodies R2B2 or R2B3 in the presence of
IPP150+ (10 mM Tris pH 7.5, 150 mM NaCl, 0.1% NP40 plus 100 μg/
mL yeast tRNA) at 4 °C for 2 h. Following binding, the complex was
washed with IPP150+ four times. Radiolabeled P and RNA were
resolved by sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) and detected by phosphorimager analysis. Where
138 M.P. Badtke et al. / Virology 390 (2009) 130–138necessary, the 35S signal of P was blocked with a sheet of exposed
autoradiography ﬁlm.
RNA binding by synthetic peptides was measured using a ﬁlter-
binding assay. Peptides (Genscript) were dissolved in TMNK plus 0.5%
NP40 and then 10 pMol (unless otherwise indicated) was applied to a
nitrocellulose ﬁlter in a slot-blot apparatus, and the ﬁlter was washed
with TMNK plus 0.5% NP40. Radiolabeled RNA or DNA dissolved in
TMNK plus 0.5% NP40 was added, the ﬁlters were washed with TMNK
plus 0.5% NP40, and the retained RNAwas detected by phosphorimage
analysis. In some experiments a 50-fold excess of non-radioactive
yeast tRNA (Sigma) was added as an irrelevant competitor. The
sequence of the Pep1 peptide is KETWWETWWTEWSQPKKKRKV and
the sequence of the UL13 peptide is APPSPPSHGGRRR. RNA binding by
miniRT2 and its derivatives was measured employing the ﬁlter-
binding assay employing 0.2 µg of protein per reaction.
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